Recent Peer-Reviewed Publication Confirms Patient Satisfaction with Multiple Allergy Immunotherapy Options
17. November 2021 09:30 ET
|
Allovate, LLC
New York, Nov. 17, 2021 (GLOBE NEWSWIRE) -- A recent article in the peer-reviewed journal International Forum of Allergy and Rhinology reported the results of a survey offered to individuals with...
Allovate Therapeutics Extends Free Allerdent® Program
23. Juli 2020 15:37 ET
|
Allovate, LLC
New York, July 23, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it has extended its free Allerdent® program. Allerdent® is a...
Allovate Therapeutics Provides Free Allerdent® To Physicians
06. Mai 2020 09:05 ET
|
Allovate, LLC
New York, May 06, 2020 (GLOBE NEWSWIRE) -- Allovate Therapeutics, a New York-based biotechnology company, announced today that it is making its allergy immunotherapy delivery platform available...
Allovate Therapeutics Appoints Bob Pomrenke as CEO
02. April 2019 14:04 ET
|
Allovate, LLC
New York, April 02, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce the...
Allovate Therapeutics Announces Grant of European Patent Covering Oral Mucosal Immunotherapy Platform
08. März 2019 10:01 ET
|
Allovate, LLC
New York, March 08, 2019 (GLOBE NEWSWIRE) -- Allovate Therapeutics (“Allovate®”), a New York-based biotechnology company focused on improving treatment for allergies, is pleased to announce that the...
Allovate Therapeutics Announces Issuance of Second Japanese Patent, Expanding Global Coverage of the Oral Mucosal Immunotherapy Platform
21. März 2018 08:37 ET
|
Allovate, LLC
New York, March 21, 2018 (GLOBE NEWSWIRE) --
Allovate Therapeutics, a biopharmaceutical company focused on improving treatment options for allergies, announced today that the...
New “Test and Treatment” Allergy Program Enables All Physicians To Provide Convenient And Effective Allergy Care
19. Dezember 2017 08:17 ET
|
Allovate, LLC
New York City, Dec. 19, 2017 (GLOBE NEWSWIRE) -- Pediatric Allergy Solutions (“PAS”) and Allovate Therapeutics (“Allovate®”) announce that they have signed an exclusive agreement to combine PAS’s...